For research use only. Not for therapeutic Use.
BO-264(Cat No.:I016174)is a potent inhibitor of the proteasome, a key cellular complex responsible for degrading misfolded or damaged proteins. By targeting and inhibiting proteasome activity, BO-264 disrupts protein turnover, leading to the accumulation of toxic proteins and inducing apoptosis in cancer cells. It has shown significant antitumor activity in preclinical studies, particularly in multiple myeloma and other malignancies that rely heavily on proteasome function for survival. BO-264 is being explored for its potential to enhance cancer therapies, especially in drug-resistant cancer cells, making it a promising candidate for further research.
Catalog Number | I016174 |
CAS Number | 2408648-20-2 |
Molecular Formula | C₁₈H₁₉N₅O₃ |
Purity | ≥95% |
Target | Apoptosis |
Storage | -20°C |
IUPAC Name | 3-(4-methoxyphenyl)-N-(2-morpholin-4-ylpyrimidin-4-yl)-1,2-oxazol-5-amine |
InChI | InChI=1S/C18H19N5O3/c1-24-14-4-2-13(3-5-14)15-12-17(26-22-15)20-16-6-7-19-18(21-16)23-8-10-25-11-9-23/h2-7,12H,8-11H2,1H3,(H,19,20,21) |
InChIKey | WRCGBYNVBFVRTN-UHFFFAOYSA-N |
SMILES | COC1=CC=C(C=C1)C2=NOC(=C2)NC3=NC(=NC=C3)N4CCOCC4 |
Reference | [1]. Akbulut O, et al. A Highly Potent TACC3 Inhibitor as a Novel Anti-cancer Drug Candidate. Mol Cancer Ther. 2020 Mar 26. pii: molcanther.0957.2019. |